Feedback Signals in Myelodysplastic Syndromes: Increased Self-Renewal of the Malignant Clone Suppresses Normal Hematopoiesis

PLoS Computational Biology

Volumn 10, Issue 4, 2014, Pages

  Walenda, Thomas ^a   Stiehl, Thomas ^b   Braun, Hanna ^a   Fröbel, Julia ^c   Ho, Anthony D ^b   Schroeder, Thomas ^c   Goecke, Tamme W ^a   Rath, Björn ^a   Germing, Ulrich ^c   Marciniak Czochra, Anna ^b   Wagner, Wolfgang ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CLONING; CYTOLOGY;

BONE MARROW; DISEASE DEVELOPMENT; FEEDBACK SIGNAL; HAEMATOPOIESIS; HAEMATOPOIETIC STEM CELLS; MYELODYSPLASTIC SYNDROMES; PROGENITOR CELL; SELF RENEWAL; SINGLE MUTATION; STEM-CELL;

STEM CELLS;

CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; STEM CELL FACTOR; THROMBOPOIETIN;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL DENSITY; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CHROMOSOME 5Q; CHROMOSOME DELETION 5; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOPENIA; DISEASE COURSE; DOWN REGULATION; FEEDBACK SYSTEM; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MULTIPOTENT STEM CELL; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PROTEIN BLOOD LEVEL; SIMULATION; STEM CELL EXPANSION; STEM CELL NICHE; UPREGULATION; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEEDBACK; HEMATOPOIESIS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 84901347739     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003599     Document Type: Article

References (62)

1. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, et al. (2012) Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 120: 2076-2086.
2. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, et al. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120: 2454-2465.
3. Pang WW, Pluvinage JV, Price EA, Sridhar K, Arber DA, et al. (2013) Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci USA 110: 3011-3016.
4. Raza A, Cruz R, Latif T, Mukherjee S, Galili N, (2010) The biology of myelodysplastic syndromes: unity despite heterogeneity. Hematol Rep 2: e4.
5. Beris P, Georgiou G, (2012) Overview of myelodysplastic syndromes. Semin Hematol 49: 287-294.
6. Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, et al. (2010) Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 363: 1025-1037.
7. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, et al. (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122: 2943-2964.
8. Mufti GJ, Potter V, (2012) Myelodysplastic syndromes: who and when in the course of disease to transplant. Hematology Am Soc Hematol Educ Program pp. 49-55.
9. Braulke F, Jung K, Schanz J, Gotze K, Muller-Thomas C, et al. (2013) Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. Leuk Res 37: 900-906.
10. Kulasekararaj AG, Mohamedali AM, Mufti GJ, (2013) Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. Br J Haematol 162: 587-605.
11. Nimer SD, (2008) MDS: a stem cell disorder-but what exactly is wrong with the primitive hematopoietic cells in this disease? Hematology Am Soc Hematol Educ Program pp. 43-51.
12. Spinelli E, Caporale R, Buchi F, Masala E, Gozzini A, et al. (2012) Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. Clin Cancer Res 18: 3079-3089.
13. Geyh S, Oz S, Cadeddu RP, Frobel J, Bruckner B, et al. (2013) Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 27: 1841-1851.
14. Aanei CM, Flandrin P, Eloae FZ, Carasevici E, Guyotat D, et al. (2012) Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. Stem Cells Dev 21: 1604-1615.
15. Pecci A, Travaglino E, Klersy C, Invernizzi R, (2003) Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow. Acta Haematol 109: 29-34.
16. Komeno Y, Kitaura J, Kitamura T, (2009) Molecular bases of myelodysplastic syndromes: lessons from animal models. J Cell Physiol 219: 529-534.
17. Ho AD, Wagner W, (2007) The beauty of asymmetry- asymmetric divisions and self-renewal in the hematopoietic system. Current Opinion in Hematology 14: 330-336.
18. Marciniak-Czochra A, Stiehl T, Ho AD, Jaeger W, Wagner W, (2009) Modeling of Asymmetric Cell Division in Hematopoietic Stem Cells- Regulation of Self-Renewal is Essential for Efficient Repopulation. Stem Cells Dev 18: 377-385.
19. Yamamoto R, Morita Y, Ooehara J, Hamanaka S, Onodera M, et al. (2013) Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell 154: 1112-1126.
20. Gorgens A, Radtke S, Mollmann M, Cross M, Durig J, et al. (2013) Revision of the human hematopoietic tree: granulocyte subtypes derive from distinct hematopoietic lineages. Cell Rep 3: 1539-1552.
21. Baccelli I, Trumpp A, (2012) The evolving concept of cancer and metastasis stem cells. J Cell Biol 198: 281-293.
22. Hope KJ, Jin L, Dick JE, (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5: 738-743.
23. Song SJ, Ito K, Ala U, Kats L, Webster K, et al. (2013) The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 13: 87-101.
24. Harada Y, Inoue D, Ding Y, Imagawa J, Doki N, et al. (2013) RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes. Blood 121: 3434-3446.
25. Roeder I, Loeffler M, (2002) A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. Exp Hematol 30: 853-861.
26. Stiehl T, Marciniak-Czochra A, (2012) Mathematical modeling of leukemogenesis and cancer stem cell dynamics. Mathematical Modelling of Natural Phenomena 7: 166-202.
27. Lander AD, Gokoffski KK, Wan FY, Nie Q, Calof AL, (2009) Cell lineages and the logic of proliferative control. PLoS Biol 7: e15.
28. Lo WC, Chou CS, Gokoffski KK, Wan FY, Lander AD, et al. (2009) Feedback regulation in multistage cell lineages. Math Biosci Eng 6: 59-82.
29. Komarova NL, (2013) Principles of regulation of self-renewing cell lineages. PLoS ONE 8: e72847.
30. Stiehl T, Ho AD, Marciniak-Czochra A, (2014) The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling. Bone Marrow Transplant 49: 30-37.
31. Walenda T, Bokermann G, Jost E, Galm O, Schellenberg A, et al. (2011) Serum after autologous transplantation stimulates proliferation and expansion of human hematopoietic progenitor cells. PLoS ONE 6: e18012.
32. Walenda T, Bokermann G, Ventura Ferreira MS, Piroth DM, Hieronymus T, et al. (2011) Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. Exp Hematol 36: 617-628.
33. Horn P, Bokermann G, Cholewa D, Bork S, Walenda T, et al. (2010) Comparison of Individual Platelet Lysates for Isolation of Human Mesenchymal Stromal Cells. Cytotherapy 12: 888-898.
34. Walenda T, Bork S, Horn P, Wein F, Saffrich R, et al. (2010) Co-Culture with Mesenchymal Stromal Cells Increases Proliferation and Maintenance of Hematopoietic Progenitor Cells. J Cell Mol Med 14: 337-350.
35. Marciniak-Czochra A, Stiehl T, Wagner W, (2009) Modeling of replicative senescence in hematopoietic development. Aging 1: 723-732.
36. Houwerzijl EJ, Blom NR, van der Want JJ, Louwes H, Esselink MT, et al. (2005) Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood 105: 3472-3479.
37. Falco P, Levis A, Stacchini A, Ciriello MM, Geuna M, et al. (2011) Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. Eur J Haematol 87: 409-418.
38. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, et al. (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104: 321-327.
39. Shen Y, Nilsson SK, (2012) Bone, microenvironment and hematopoiesis. Curr Opin Hematol 19: 250-255.
40. Lu J, Sun Y, Nombela-Arrieta C, Du KP, Park SY, et al. (2012) Fak depletion in both hematopoietic and nonhematopoietic niche cells leads to hematopoietic stem cell expansion. Exp Hematol 40: 307-317.
41. Colijn C, Mackey MC, (2005) A mathematical model of hematopoiesis-I. Periodic chronic myelogenous leukemia. J Theor Biol 237: 117-132.
42. Ostby I, Kvalheim G, Rusten LS, Grottum P, (2004) Mathematical modeling of granulocyte reconstitution after high-dose chemotherapy with stem cell support: effect of post-transplant G-CSF treatment. J Theor Biol 231: 69-83.
43. Agarwal A, (2012) MDS: roadblock to differentiation. Blood 120: 1968-1969.
44. Davids MS, Steensma DP, (2010) The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther 10: 309-319.
45. Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, et al. (2009) JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell 15: 341-352.
46. Perrotti D, Jamieson C, Goldman J, Skorski T, (2010) Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 120: 2254-2264.
47. Song SJ, Ito K, Ala U, Kats L, Webster K, et al. (2013) The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 13: 87-101.
48. Harada Y, Inoue D, Ding Y, Imagawa J, Doki N, et al. (2013) RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes. Blood 121: 3434-3446.
49. Issa JP, (2013) The myelodysplastic syndrome as a prototypical epigenetic disease. Blood 121: 3811-3817.
50. Vasilatou D, Papageorgiou SG, Dimitriadis G, Pappa V, (2013) Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes. Epigenetics 8: 561-570.
51. Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, et al. (2013) Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Crit Rev Oncol Hematol 88: 231-245.
52. Jost E, Lin Q, Weidner CI, Wilop S, Hoffmann M, et al. (2013) Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. Leukemia [epub ahead of print]: doi:10.1038/leu.2013.362.
53. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, et al. (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506: 328-333.
54. Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, et al. (2012) Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 44: 1179-1181.
55. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, et al. (2012) Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 366: 1090-1098.
56. Geyer JT, Verma S, Mathew S, Wang YL, Racchumi J, et al. (2013) Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q). Hum Pathol 44: 346-356.
57. Kadereit S, Deeds LS, Haynesworth SE, Koc ON, Kozik MM, et al. (2002) Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer. Stem Cells 20: 573-582.
58. Chen YM, Whang-Peng J, Liu JM, Kuo BI, Wang SY, et al. (1996) Serum cytokine level fluctuations in chemotherapy-induced myelosuppression. Jpn J Clin Oncol 26: 18-23.
59. Bouronikou E, Georgoulias P, Giannakoulas N, Valotassiou V, Palassopoulou M, et al. (2013) Metabolism-related cytokine and hormone levels in the serum of patients with myelodysplastic syndromes. Acta Haematol 130: 27-33.
60. Broxmeyer HE, (2013) Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med 210: 205-208.
61. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, et al. (2013) BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 123: 1542-1555.
62. Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, et al. (2013) Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 121: 3658-3665.